Phase I Trial of Intratumoral Bi-functional shRNA Stathmin 1-knockdown Lipoplex in Patients With Advanced and/or Metastatic Cancer View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2012-2017

ABSTRACT

This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients with superficially accessible advanced cancer following prior therapies will be entered into the study following a modified dose escalation design based on the demonstrated safety of our previous clinical experience (BB-IND 13744) with the same liposome and vector DNA backbone expressing a different transgene (of which doses up to 7 mg DNA IV/single dose have been administered). Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema (100%-50%-33%-33%) at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose. Should a single, but not more than two (2), ≥ Grade 3 Dose Limiting Toxicity (DLT) occur in any cohort, following mandated review (see below) an additional two (2) patients will be accrued at that dose (total of six). If more than one ≥ Grade 3 toxicity occurs in any cohort, the preceding dose cohort will be expanded to six (from four) and if < 2/6 patients experience ≥ Grade 3 toxicity, that dose will be the Phase II recommended dose. Should no ≥ Grade 3 toxicity occur in any cohort (other than Grade 3 local injection site reaction), an additional two (2) patients will be treated at 0.053 mg/kg DNA intratumoral / single dose. More... »

URL

https://clinicaltrials.gov/show/NCT01505153

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3164", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA\u2122STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA\u2122 STMN1 LP administered by a single intratumoral (IT) injection. Patients with superficially accessible advanced cancer following prior therapies will be entered into the study following a modified dose escalation design based on the demonstrated safety of our previous clinical experience (BB-IND 13744) with the same liposome and vector DNA backbone expressing a different transgene (of which doses up to 7 mg DNA IV/single dose have been administered). Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema (100%-50%-33%-33%) at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose. Should a single, but not more than two (2), \u2265 Grade 3 Dose Limiting Toxicity (DLT) occur in any cohort, following mandated review (see below) an additional two (2) patients will be accrued at that dose (total of six). If more than one \u2265 Grade 3 toxicity occurs in any cohort, the preceding dose cohort will be expanded to six (from four) and if < 2/6 patients experience \u2265 Grade 3 toxicity, that dose will be the Phase II recommended dose. Should no \u2265 Grade 3 toxicity occur in any cohort (other than Grade 3 local injection site reaction), an additional two (2) patients will be treated at 0.053 mg/kg DNA intratumoral / single dose.", 
    "endDate": "2017-04-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01505153", 
    "keywords": [
      "Phase I trial", 
      "stathmin", 
      "in-patient", 
      "metastatic cancer", 
      "safety trial", 
      "Bovine Immunodeficiency Virus", 
      "lipoplexes", 
      "LPS", 
      "IT", 
      "injection", 
      "patient", 
      "advanced cancer", 
      "prior therapy", 
      "dose escalation", 
      "safety", 
      "IND", 
      "liposome", 
      "DNA backbone", 
      "transgene", 
      "dose", 
      "DNA", 
      "accrue", 
      "escalation", 
      "single dose", 
      "grade 3", 
      "dose-limiting toxicity", 
      "cohort", 
      "review", 
      "toxicity", 
      "recommended dose", 
      "injection site reaction"
    ], 
    "name": "Phase I Trial of Intratumoral Bi-functional shRNA Stathmin 1-knockdown Lipoplex in Patients With Advanced and/or Metastatic Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01505153"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00011.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.416487.8", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.428808.e", 
        "type": "Organization"
      }
    ], 
    "startDate": "2012-02-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/cgt.2010.35", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026134991", 
          "https://doi.org/10.1038/cgt.2010.35"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/14737140.8.9.1461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034572289"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/dna.2011.1240", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059252587"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01505153"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01505153'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01505153'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01505153'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01505153'


 

This table displays all metadata directly associated to this object as RDF triples.

62 TRIPLES      16 PREDICATES      50 URIs      40 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01505153 schema:about anzsrc-for:3164
2 schema:description This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients with superficially accessible advanced cancer following prior therapies will be entered into the study following a modified dose escalation design based on the demonstrated safety of our previous clinical experience (BB-IND 13744) with the same liposome and vector DNA backbone expressing a different transgene (of which doses up to 7 mg DNA IV/single dose have been administered). Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema (100%-50%-33%-33%) at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose. Should a single, but not more than two (2), ≥ Grade 3 Dose Limiting Toxicity (DLT) occur in any cohort, following mandated review (see below) an additional two (2) patients will be accrued at that dose (total of six). If more than one ≥ Grade 3 toxicity occurs in any cohort, the preceding dose cohort will be expanded to six (from four) and if < 2/6 patients experience ≥ Grade 3 toxicity, that dose will be the Phase II recommended dose. Should no ≥ Grade 3 toxicity occur in any cohort (other than Grade 3 local injection site reaction), an additional two (2) patients will be treated at 0.053 mg/kg DNA intratumoral / single dose.
3 schema:endDate 2017-04-01T00:00:00Z
4 schema:keywords Bovine Immunodeficiency Virus
5 DNA
6 DNA backbone
7 IND
8 IT
9 LPS
10 Phase I trial
11 accrue
12 advanced cancer
13 cohort
14 dose
15 dose escalation
16 dose-limiting toxicity
17 escalation
18 grade 3
19 in-patient
20 injection
21 injection site reaction
22 lipoplexes
23 liposome
24 metastatic cancer
25 patient
26 prior therapy
27 recommended dose
28 review
29 safety
30 safety trial
31 single dose
32 stathmin
33 toxicity
34 transgene
35 schema:name Phase I Trial of Intratumoral Bi-functional shRNA Stathmin 1-knockdown Lipoplex in Patients With Advanced and/or Metastatic Cancer
36 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01505153
37 schema:sdDatePublished 2019-03-07T15:24
38 schema:sdLicense https://scigraph.springernature.com/explorer/license/
39 schema:sdPublisher N58117b8ac33c4326a9e95369b3980d5e
40 schema:sponsor https://www.grid.ac/institutes/grid.416487.8
41 https://www.grid.ac/institutes/grid.428808.e
42 schema:startDate 2012-02-01T00:00:00Z
43 schema:subjectOf sg:pub.10.1038/cgt.2010.35
44 https://doi.org/10.1089/dna.2011.1240
45 https://doi.org/10.1586/14737140.8.9.1461
46 schema:url https://clinicaltrials.gov/show/NCT01505153
47 sgo:license sg:explorer/license/
48 sgo:sdDataset clinical_trials
49 rdf:type schema:MedicalStudy
50 N58117b8ac33c4326a9e95369b3980d5e schema:name Springer Nature - SN SciGraph project
51 rdf:type schema:Organization
52 anzsrc-for:3164 schema:inDefinedTermSet anzsrc-for:
53 rdf:type schema:DefinedTerm
54 sg:pub.10.1038/cgt.2010.35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026134991
55 https://doi.org/10.1038/cgt.2010.35
56 rdf:type schema:CreativeWork
57 https://doi.org/10.1089/dna.2011.1240 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059252587
58 rdf:type schema:CreativeWork
59 https://doi.org/10.1586/14737140.8.9.1461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034572289
60 rdf:type schema:CreativeWork
61 https://www.grid.ac/institutes/grid.416487.8 schema:Organization
62 https://www.grid.ac/institutes/grid.428808.e schema:Organization
 




Preview window. Press ESC to close (or click here)


...